Filing Details
- Accession Number:
- 0001649094-25-000002
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-01-03 18:07:22
- Reporting Period:
- 2025-01-02
- Accepted Time:
- 2025-01-03 18:07:22
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1649094 | Vaxcyte Inc. | PCVX | Biological Products, (No Disgnostic Substances) (2836) | 464233385 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1813798 | Jim Wassil | C/O Vaxcyte, Inc. 825 Industrial Road, Ste. 300 San Carlos CA 94070 | Chief Operating Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2025-01-02 | 8,000 | $2.42 | 213,695 | No | 4 | M | Direct | |
Common Stock | Disposition | 2025-01-02 | 1,356 | $82.88 | 212,339 | No | 4 | S | Direct | |
Common Stock | Disposition | 2025-01-02 | 5,483 | $83.69 | 206,856 | No | 4 | S | Direct | |
Common Stock | Disposition | 2025-01-02 | 1,161 | $84.43 | 205,695 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2025-01-02 | 8,000 | $0.00 | 8,000 | $2.42 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
10,638 | 2029-12-16 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $82.31 to $83.265. The reporting person will provide upon request to the SEC, the issuer or security holder of theissuer, full information regarding the number of shares sold at each separate price.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $83.31 to $84.215. The reporting person will provide upon request to the SEC, the issuer or security holder of theissuer, full information regarding the number of shares sold at each separate price.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $84.315 to $84.55. The reporting person will provide upon request to the SEC, the issuer or security holder of theissuer, full information regarding the number of shares sold at each separate price.
- 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter.